NCT03977727View on ClinicalTrials.gov

FIasp® vs. Novolog® in Type 1 Diabetics Using 670G Medtronic Pump

PHASE3CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 11, 2019

Primary Completion Date

March 9, 2020

Study Completion Date

April 20, 2020

Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG

Fiasp®

Fiasp® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system

DRUG

Novolog®

Novolog® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system

DEVICE

670G hybrid closed loop continuous subcutaneous insulin infusion system

CSII

Trial Locations (1)

78731

Texas Diabetes & Endocrinology, Austin

All Listed Sponsors
lead

Texas Diabetes & Endocrinology, P.A.

OTHER

NCT03977727 - FIasp® vs. Novolog® in Type 1 Diabetics Using 670G Medtronic Pump | Biotech Hunter | Biotech Hunter